Join to view full profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3000
Dr. Lindsley is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2010
WashU MedicineClass of 2008, M.D., Ph.D.
Certifications & Licensure
MA State Medical License 2011 - 2028
Publications & Presentations
PubMed
- Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.Katharina Fleischhauer, Cristina Toffalori, Federica Cugnata, Jan A Hofmann, Giorgio Orofino
Journal of Clinical Oncology. 2026-08-10 - 1 citationsZRSR2 loss causes aberrant splicing in JAK2-driven myeloproliferative neoplasm but is not sufficient to drive disease progression.Ranran Zhang, Jasmin Straube, Yashaswini Janardhanan, Rohit Haldar, Leanne Cooper
Hemasphere. 2025-09-01 - 47 citationsSingle-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths.Mariela Cortés-López, Paulina Chamely, Allegra G Hawkins, Robert F Stanley, Ariel D Swett
Cell Stem Cell. 2023-09-07
Abstracts/Posters
- Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS StudyR. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...R. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant AbstractR. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
